**Please use the following form to submit your NON-CONFIDENTIAL Small Molecule Accelerator Project Proposal.**

***Please limit the total length of your pre-proposal to 2 pages*.**

**INVESTIGATOR NAME:**

**INVESTIGATOR HOSPITAL/ACADEMIC AFFILIATION:**

**PROJECT TITLE:**

**PFIZER COMPOUNDS REQUESTED (and amount):**

**SCIENTIFIC HYPOTHESIS and RATIONALE:**

This section should contain:

1. A brief description of the target/pathway and link to human disease and disease mechanism(s). Please indicate the novelty of this target or approach relevant to disease mechanism.
2. What is/are the unmet medical need(s) this target/pathway could address?
3. Key evidence available to support the hypothesis above and demonstration of target validation (i.e. human genetic, human tissue, preclinical animal models)

**RESEARCH PLAN:**

This section should contain:

1. A description of the research plan, including objectives and specific aims, to be carried out with the Pfizer compound.
2. Specify the readouts of your studies and potential outcomes. What is the time frame for completing this work? Describe your Go/No Go decision based on results with testing the Pfizer compound.

**BIOGRAPHICAL SKETCH OF PRINCIPAL INVESTIGATOR:**

Please provide a brief bio-sketch of the PI and key publications. Attachment of NIH biosketch is acceptable.

**SCOPE/ADDITONAL INFORMATION:**

***What CTI is looking for***: A well supported hypothesis and strong rationale for the target/pathway in human health and disease, in a therapeutic indication of interest to Pfizer, which include: Oncology: Immuno-oncology, epigenetics, novel tumor specific cell surface antigens, and targets identified by unique insights in tumor biology, Inflammation and Immune disorders: Fibrosis, NASH, Crohn’s and Colitis, microbiome-epithelial interactions, and epithelial barrier protection, Cardiovascular and metabolic diseases: dysfunctional cardiac metabolism, vascular inflammatory processes, and cardiac fibrosis, Neuroscience: neuroinflammation, neurodegenerative disorders, remyelination, misfolded proteins, Alzheimer's Disease, Parkinson’s Disease, and Multiple Sclerosis, Rare monogenic genetic diseases. Further information about Pfizer’s therapeutic areas of interest can be found at: <https://www.pfizer.com/research/therapeutic_areas>

***What CTI is NOT looking for***: As the Small Molecule Accelerator program is aimed at assessing the role of a specific target in defined indications, this is not a broad screening collaboration and therefore screening the entire available compound set is out of scope.